Could Topical Delgocitinib Treat Capecitabine-Associated Hand–Foot Syndrome?

1

Capecitabine-associated hand–foot syndrome can impair quality of life and require anticancer treatment modification or discontinuation.
2

Two patients with grade 3 capecitabine-induced hand–foot syndrome despite clobetasol and urea received topical delgocitinib twice daily for 6 weeks.
3

One patient’s CTCAE grade improved from 3 to 1 and HFS-14 score from 73.5 to 17.6, allowing capecitabine to continue.
4

The other patient’s CTCAE grade remained 3 and HFS-14 score changed from 76.5 to 67.6, necessitating capecitabine interruption.
5

These discordant outcomes in two patients cannot establish delgocitinib efficacy, and larger prospective studies are needed to define its role in hand–foot syndrome.

1